Icariin ameliorates minimal change disease by regulating the mitochondrial dysfunction pathway: an integrated strategy of network pharmacology, bioinformatics, and experimental validation
<i>ANPEP</i> and <i>XDH</i> were identified as associated with ICA therapy and MDRGs in MCD patients. Furthermore, the potential ameliorating effect of ICA on MCD could be achieved by alleviating mitochondrial dysfunction. This work provides a potential theoretical basis for the treatment of MCD.
Authors
- Diansheng Zhong (ORCID: https://orcid.org/0000-0001-6483-8134)
- Enlai Dai (ORCID: https://orcid.org/0009-0005-9037-9927)
- Guozhong Xue
- Li Chen (ORCID: https://orcid.org/0000-0002-7006-4443)
- Zhang Li (ORCID: https://orcid.org/0000-0002-5408-8963)
- Hanyu Wang (ORCID: https://orcid.org/0000-0002-7584-6815)
- Hao Wu (ORCID: https://orcid.org/0000-0002-1154-3743)
- Rong Wu (ORCID: https://orcid.org/0009-0008-0583-7463)
Institutions
- Gansu University of Traditional Chinese Medicine (CN)
- Northwest Institute of Mining and Metallurgy (CN)
- First Hospital of Lanzhou University (CN)
- Lanzhou University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-08-29
- DOI
- https://doi.org/10.3389/fphar.2025.1640822
- Citations
- 1
- Primary Topic
- Medicinal Plant Pharmacodynamics Research
- Type
- article
- Field-Weighted Citation Impact
- 1.56